Lineage Cell Therapeutics announced Dec. 20 that it had entered into an exclusive worldwide collaboration and license agreement with Genentech, a member of the Roche group, for the development and commercialization of Lineage’s retinal pigment epithelium (RPE) cell therapy OpRegen. OpRegen, delivered subretinally in a single injection, targets advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA)